265 related articles for article (PubMed ID: 1489869)
1. [Erythropoietin--physiology and therapeutic potentialities].
Möllmann M
Anasthesiol Intensivmed Notfallmed Schmerzther; 1992 Dec; 27(8):461-8. PubMed ID: 1489869
[TBL] [Abstract][Full Text] [Related]
2. [Chemical structure, biotechnical production and clinical use of recombinant erythropoietin].
Fandrey JK; Jelkmann WE
Z Gesamte Inn Med; 1992 Jun; 47(6):231-8. PubMed ID: 1642021
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin deficiency and relative resistance cause anaemia in post-renal transplant recipients with normal renal function.
Nampoory MR; Johny KV; al-Hilali N; Seshadri MS; Kanagasabhapathy AS
Nephrol Dial Transplant; 1996 Jan; 11(1):177-81. PubMed ID: 8649630
[TBL] [Abstract][Full Text] [Related]
4. [Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study].
Sinnassamy P; Andre JL; Treize G; Leroy B
Arch Fr Pediatr; 1993 Mar; 50(3):201-8. PubMed ID: 8338412
[TBL] [Abstract][Full Text] [Related]
5. [Recombinant erythropoietin in autologous blood donation].
von Bormann B; Weidler B; Friedrich M; von Andrian-Werburg H
Anaesthesist; 1991 Jul; 40(7):386-90. PubMed ID: 1928712
[TBL] [Abstract][Full Text] [Related]
6. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin: mechanisms of action and indications for treatment.
Vreugdenhil G; Frenken LA; Koene RA
Neth J Med; 1993 Jun; 42(5-6):187-202. PubMed ID: 8377877
[TBL] [Abstract][Full Text] [Related]
8. [Erythropoietin].
Kubanek B; Rich I; Noé G
Infusionsther Transfusionsmed; 1994 Nov; 21 Suppl 3():46-50. PubMed ID: 7531047
[TBL] [Abstract][Full Text] [Related]
9. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices.
Trkulja V
Med Hypotheses; 2012 Jan; 78(1):157-61. PubMed ID: 22078846
[TBL] [Abstract][Full Text] [Related]
10. [Physiology of eryhtropoietin and its therapeutic use].
Casadevall N
Ann Pharm Fr; 1996; 54(4):151-6. PubMed ID: 8881101
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.
Cody J; Daly C; Campbell M; Donaldson C; Grant A; Khan I; Pennington S; Vale L; Wallace S; MacLeod A
Cochrane Database Syst Rev; 2001; (4):CD003266. PubMed ID: 11687180
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin-- measurement and clinical applications.
Marsden JT
Ann Clin Biochem; 2006 Mar; 43(Pt 2):97-104. PubMed ID: 16536911
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of anemia in chronic hemodialysis patients with recombinant human erythropoietin: long-term results in 15 patients].
Jacquot C; Berthelot JM; Chiappini-Judith D; Ferragu-Haguet M; Lefebvre A; Masselot JP; Moynot A; Frydman MO; Peterlongo F
Nephrologie; 1990; 11(1):11-6. PubMed ID: 2374641
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin and chronic lymphocytic leukemia.
Mauro FR; Gentile M; Foa R
Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
[TBL] [Abstract][Full Text] [Related]
15. [Clinical applications of erythropoietin].
Robak T
Acta Haematol Pol; 1994; 25(2 Suppl 1):112-23. PubMed ID: 8067196
[TBL] [Abstract][Full Text] [Related]
16. [The clinical impact of the physiological effects of erythropoietin and erythropoietin-stimulating agents on the incidence of malignancy, and hypertension: beyond anaemia].
Ortega LM; Contreras G
Nefrologia; 2009; 29(4):288-94. PubMed ID: 19668298
[TBL] [Abstract][Full Text] [Related]
17. [Influence of long-term human recombinant erythropoietin treatment on secretion of pancreatic polypeptide and gastrin in hemodialysed patients with chronic renal failure].
Nieszporek T; Kokot F; Wiecek A; Marcinkowski W; Rudka R; Trembecki J
Przegl Lek; 1995; 52(12):590-3. PubMed ID: 8834657
[TBL] [Abstract][Full Text] [Related]
18. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug.
Jelkmann W
Curr Pharm Biotechnol; 2000 Jul; 1(1):11-31. PubMed ID: 11467358
[TBL] [Abstract][Full Text] [Related]
19. [The effect of recombinant erythropoietin on candidicidal activity of polymorphonuclear leukocytes in hemodialyzed patients].
Bartůnková J; Sulková S; Cebecauer M
Cas Lek Cesk; 1995 Dec; 134(23):756-9. PubMed ID: 8599817
[TBL] [Abstract][Full Text] [Related]
20. [Overview of erythropoietin].
Lacombe C; Mayeux P; Casadevall N
Nephrologie; 1991; 12(5):221-6. PubMed ID: 1662784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
